We recently published 10 Stocks Leaving Wall Street in the Dust; 4 Hit Fresh Records. Moderna Inc. (NASDAQ:MRNA) was one of ...

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...

Opportunities in the mRNA quality monitoring market include the rising demand for QC due to the expansion of mRNA ...

An LMU research team led by Professor Olivia M. Merkel, Chair of Drug Delivery at LMU, has developed a new delivery system ...

The safety of mRNA vaccines, hailed as a saviour in the covid-19 pandemic, has been called into question by the US ...

Moderna is up 20% YTD, with a golden cross suggesting a trend reversal. Momentum indicators make it a top 2026 pick.

A trio of mRNA molecules could help guard against the harmful effects of aging on immune cells, a study in mice finds. A new ...

MIT researchers have developed an experimental mRNA-based therapy that restored key immune functions lost with age in mice.

Filed in a Delaware federal court, the lawsuits claim the companies copied technology developed by Bayer's subsidiary, ...

The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.

Bayer's Monsanto sued COVID-19 vaccine makers Pfizer , BioNTech and Moderna in Delaware federal court on Tuesday for ...